Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 15:34:54 17/07/2024 BST			5-day change	1st Jan Change
73.24 ^USD	+2.23%		+7.16%	-9.06%

03:21pm	Gilead Sciences Chief Medical Officer Merdad Parsey to Leave	MT
03:21pm	Gilead Sciences Chief Medical Officer to Step Down	DJ

Gilead Sciences Eyes Acquisitions

January 06, 2017 at 05:00 am

Gilead Sciences Inc. (NasdaqGS:GILD) is planning on making a strategic acquisition.

Latest news about Gilead Sciences, Inc.

Gilead Sciences Chief Medical Officer Merdad Parsey to Leave	02:21pm	MT
Gilead Sciences Chief Medical Officer to Step Down	02:21pm	DJ
Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating	07-16	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78	07-11	MT
RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating	07-09	MT
Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93	07-08	MT
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	07-01	MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	07-01	CI
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	06-27	CI
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	06-26	MT
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	06-25	CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	06-24	MT
Tech overload on Wall Street	06-21
Wall Street set for muted open as investors await business survey data	06-21	RE
Nvidia Slide Stifles US Equity Futures Pre-Bell	06-21	MT
Top Premarket Gainers	06-21	MT
Wall Street futures edge lower ahead of business survey data	06-21	RE
Equity Markets Close Mixed as Investors Weigh Economic Data	06-20	MT
Equity Markets Close Mixed After Macro Data	06-20	MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup	06-20	DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data	06-20	MT
Sector Update: Health Care Stocks Higher Late Afternoon	06-20	MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon	06-20	MT
Equity Markets Mixed as Traders Weigh Macro Data	06-20	MT
Sliding Technology Stocks Push S&P 500, Nasdaq Composite Lower	06-20	MT

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

71.64 USD

Average target price

83.01 USD

Spread / Average Target

+15.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GILEAD SCIENCES, INC.	-9.06%	89.25B
ELI LILLY AND COMPANY	+56.97%	848B
NOVO NORDISK A/S	+33.32%	627B
JOHNSON & JOHNSON	-0.27%	363B
MERCK & CO., INC.	+15.53%	318B
ABBVIE INC.	+12.70%	299B
ASTRAZENECA PLC	+15.04%	243B
NOVARTIS AG	+16.98%	225B
AMGEN INC.	+16.49%	179B
PFIZER, INC.	+4.58%	167B

Other Pharmaceuticals

Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Gilead Sciences Eyes Acquisitions

Latest news about Gilead Sciences, Inc.

Chart Gilead Sciences, Inc.

Company Profile

Income Statement Evolution

Ratings for Gilead Sciences, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals